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Introduction
Wernicke’s encephalopathy (WE) is a neurological syndrome most 
commonly found in patients suffering from alcohol abuse. It is less 
frequently diagnosed in non-alcoholic patients. In non-alcoholic 
patients WE might develop due to the exclusion of upper portions of 
the gastrointestinal tract (e.g. after gastrectomy, gastrojejunostomy, 
gastric bypass surgery) or secondary to intractable vomiting, 
inadequate dietary intake or malabsorption.1,2 Other described 
conditions in which WE may develop include HIV/AIDS, several types 
of malignancy (inoperable gastric cancer, leukaemia and lymphoma), 
prolonged periods of malnutrition (anorexia), hyperemesis 
gravidarum, thyroid conditions, post organ transplant as well as 
patients receiving dialysis and long-term dependency on parenteral 
nutrition (PN).1-3,4 
WE is caused by thiamin (vitamin B1) deficiency.
1,2 This micronutrient, 
a water-soluble vitamin, is absorbed primarily in the duodenum, 
acts as a co-factor in carbohydrate metabolism, and is important 
in neuron cell function.3 The human body cannot synthesize thiamin 
and regular dietary intake of thiamin is essential.3 Symptoms of a 
thiamin deficiency or WE include the classic triad of ophthalmoplegia/
nystagmus, ataxia and encephalopathy/confusion,1-3 although these 
clinical symptoms occur in only 16–25% of patients.3,4,5 Early 
onset of a thiamin deficiency includes general symptoms of illness 
such as headaches, irritability, fatigue and abdominal discomfort.3 
Prophylactic thiamin supplementation forms part of the standard 
nutritional management of patients at risk of developing refeeding 
syndrome (RFS).6,7 RFS, also a regularly underdiagnosed condition,4 
is characterized by the potentially fatal shift in fluids and electrolytes 
(decrease in phosphate, potassium and magnesium), as well as 
thiamin deficiency which could possibly contribute to WE.4,6,7 These 
findings emphasize the importance for medical doctors as well 
as dietitians to be aware of the signs and symptoms of thiamin 
deficiency, particularly in cases with a non-alcoholic aetiology. 
Case Report 
A 32-year-old female was referred to the upper gastrointestinal 
surgical unit at Groote Schuur Hospital with a one-year history of 
loss of appetite, poor oral intake, intermittent postprandial vomiting 
and significant loss of weight. Collateral history elucidated an acute 
deterioration in cognitive and muscle function over the preceding 
month. An initial gastroscopy by the referring hospital had shown 
severe gastritis, a prepyloric mass and gastric outlet obstruction 
(GOO). An abdominal ultrasound reported an abnormally thickened 
appearance of the gastric mucosa. Repeat gastric biopsies were 
consistent with a diffuse-type gastric adenocarcinoma involving most 
of the distal stomach and pylorus. Staging computed tomography 
(CT) revealed a locally unresectable diffuse gastric cancer.
Anthropometry
The patient was unable to stand, and therefore the relevant 
anthropometric measurements were estimated. A body mass index 
(BMI) of 19 kg/m2 and height of 1.72 m were estimated, resulting in 
an estimated current body weight of 56 kg. An ideal body weight of 
65kg, at BMI of 22 kg/m2, was calculated. The patient had visible 
temporal and deltoid wasting, with 5–10% weight loss over the 
preceding 6–12 months.  
Biochemistry
The biochemical workup included a full blood count, serum urea, 
creatinine, electrolytes, calcium, magnesium, phosphate and albumin, 
as well as liver function tests. The relevant serial blood values are 
shown in Table 1. The patient had ongoing borderline hypokalaemia 
due to increased losses from prolonged vomiting. Serum creatinine 
levels reflect muscle mass as creatinine is mostly derived from the 
breakdown of endogenous sources, and less affected by catabolic 
states than urea levels.8 Thus, the decreased creatinine levels in 
the patient reflected her low muscle mass, corresponding with the 
quadriparesis (see clinical assessment) and muscle wasting. Urea, 
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on the other hand, is derived from either dietary protein sources 
or endogenous protein sources and its formation is influenced by 
protein intake, increased catabolism (either due to starvation or an 
acute phase response), as well as the absorption of protein from 
blood in the gastrointestinal lumen.8 The hypophosphatemia on day 
1 was not an indication of RFS since nutritional intervention only 
commenced on that day, but was rather a result of increased losses 
and poor dietary intake. Hypomagnesemia may be attributed to poor 
absorption, or rather diminished nutrient delivery due to GOO, as the 
absorption site for magnesium is in the small intestine and colon.10 
Hypoalbuminemia is an indicator of the catabolic state due to the 
adenocarcinoma.8  
Clinical
On arrival at our centre, the patient was bedridden and aphasic with 
a flaccid, areflexic quadriparesis, bilateral cranial nerve VI palsies, 
nystagmus, ptosis and encephalopathy. General wasting and fatigue 
with thin and weakened extremities were observed. The patient was 
apyrexial with stable vitals. According to collateral family history, she 
suffered from severe depression which was never formally diagnosed 
or treated, but had been fully independent and functional up until one 
month prior to presentation. A subsequent CT brain scan excluded 
metastatic disease. Psychiatry and neurology were consulted on 
day 1 and 4 respectively, and a subsequent diagnosis of WE due to 
severe thiamin deficiency was made on clinical grounds. A magnetic 
resonance imaging (MRI) of the brain showed no characteristic 
findings of WE or any other permanent lesions.
Dietary
The patient was identified as being at risk of developing RFS due to 
her prolonged inadequate intake and increased weight and nutrient 
losses. She was kept nil per os due to complete GOO, and total 
parenteral nutrition (PN) was initiated. An indication for PN according 
to European Society for Clinical Nutrition and Metabolism (ESPEN) in 
unresectable cancer patients includes supportive or supplementary 
PN, if a patient is likely to suffer from starvation prior to tumour 
spread, although, in most cases, the nutritional benefit is outweighed 
by the risk of infection, sepsis and or PN-associated liver disease 
with prolonged administration. Thus PN support in advanced cancer 
is not standard practice.9,10
PN support was commenced according to the National Institute for 
Health and Care Excellence (NICE) guidelines for the management 
and prevention of RFS.9,10,11 The guidelines (Figure 1) recommend 
slow commencement of nutrition at 10  kcal/kg/day with an 
increase of 5 kcal/kg/day based on biochemical monitoring, along 
with intravenous (IV) thiamin supplementation and prophylactic 
IV phosphate, potassium and magnesium supplementation.9,10,11 
Regular repeat blood as well as glycaemic monitoring was strictly 
adhered to. 
The patient’s initial energy needs were calculated at 15 kcal/kg/day 
(based on estimated actual weight) due to the 330 kcal (5.8 kcal/
kg/day based on estimated actual weight) that was already being 
received from the 5% Dextrose IV infusion @ 63  ml/hour since 
admission. The patient was prescribed an all-in-one PN bag, started 
at 60 ml/hour via central venous access. Additional IV micronutrient 











Admission Day1 Day 2 Day 3 Day 4 Day 8 Day 11 Day 18 Day 21 Day 27
Sodium 135–147 mmol/l–1 141 139 141 140 138 137 141 138 139 140 141 144
Potassium 3.3–5.3 mmol/l–1 2.4 H ¥ 3.0 3.6 3.9 3.1 3.5 3.4 3.4 3.2 2.7 2.8
Urea 2.6–7.0 mmol/l–1 3.0 3.4 4.6 5.1 3.9 4.6 3.6 3.4 6.4 9.8
Creatinine 60–120 µmol.L–1 30 39 39 30 23 22 21 35 22
Haemoglobin 14.3–18.3 g/dL 10.6 13.7 11.8 9.7 10.1 9.0 7.9 8.7 10.0 9.3 9.1





2.0 1.9 1.9 2.1 2.2 2.05 2.2 2.4 2.4
Magnesium 0.65–1.1 mmol/l–1 0.7 0.79 0.60 0.64 0.63 0.87 0.54 0.75
Phosphate 0.8–1.4 mmol/l–1 0.84 0.68 0.8 1.02 1.56 1.14 1.15 0.62
Albumin 35–52 g/L 27 29 32 30 28 23
ALT ¥ 5–40 U/L 37 42 9 <5 8
AST ¥ 5–40 U/L 20 35 16 12 17
ALP ¥ 40–120 U/L 48 93 85 74 130
GGT ¥ 0–60 U/L 30 121 67 42 45
Vitamin B12 145–569 380
TSH ¥ 0.27–4.20 mIU/L 2.84
 ¥ H: Haemolysed; WBC: White blood count; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphate                      
GGT: gamma glutamyl transpeptidase; TSH: Thyroid stimulating hormone
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solution (containing one ampule Soluvit® and one ampule Additrace® 
in 200  ml saline, given over 4 hours) was administered to reach 
daily micronutrient requirements as the whole PN bag was not 
used. Normal saline IV fluids with 40 mmol KPO4 (42 ml/hour) was 
commenced to provide total fluids up to 40  ml/kg/day, based on 
estimated actual weight. 
On diagnosis of gastric adenocarcinoma, the patient’s goal energy 
and protein were adjusted to disease specific recommendations 
according to the ESPEN guidelines on PN: non-surgical oncology of 
25–30 kcal/kg/day and protein recommendations at a minimum of 
1 g/kg/day with a target range of 1.2–2 g/kg/day.9,10 For prevention 
of further weight loss and/or weight gain, a total energy intake up to 
40 kcal/kg/day is recommended.12 This resulted in 1680–2240 kcal/
day (based on estimated current weight) and 78–130 g/day protein 
(based on ideal body weight). Her fluid requirement was continued 
at 40 ml/kg/day to maintain her fluid balance.
Medical management
The patient was initially prescribed Pantoprazole®, Clexane®, 
Perfalgan®, Stemetil®, and Morphine®.  Prophylactic IV potassium 
phosphate (KPO4) and IV thiamin supplementation (200  mg 
immediately prior to initiation of PN and continuing 100 mg daily for 
10 days) was started according to the NICE guidelines (Figure 1).11,12 
The peripherally administered 5% Dextrose infusion at 63 ml/hour 
was changed to normal saline with the commencement of PN. Based 
on the biochemical result done on day 2, IV magnesium sulphate (2 
grams in 200 ml saline daily) supplementation was started.
IV thiamin supplementation was adjusted according to WE protocols 
on day 4 (Figure 2). It is inadvisable to prolong infusion for more than 
30 minutes as it can be painful at the infusion site.4 
By day 10, the patient’s cognitive state improved and she was 
orientated to person, place and time, nystagmus resolved and she 
gained 3 out of 5 power in her upper limbs, although her lower 
limb weakness persisted. Occupational therapy was consulted and 
provided bilateral ankle foot orthosis (AFO) splints for foot drop. 
Nutritional Management
The patient was started on PN according to the NICE guidelines 
for the management of RFS (Table 2). The patient tolerated the 
feeding regimen well and reached maximum requirements by day 
4. Prophylactic supplementation of IV thiamin as well as KPO
4 was 
continued and, on day 4, magnesium was also added due to deficient 
levels. Thiamin supplementation was adjusted on day 5 and the 
patient volunteered an increase in appetite, although she still had 
nil oral tolerance. 
On day 22, an uncovered 120 x 20  mm duodenal self-expanding 
metal stent (SEMS) was placed endoscopically, but failed to expand 
due to the severity of her gastric outlet stenosis and external 
compression from the tumor (Figure 3). As a last resort to establish 
an enteral feeding route, the patient was booked for a palliative open 
gastrojejunostomy. On commencement of her laparotomy, however, 
the procedure was abandoned due to the diffuse, locally-advanced 
nature of her disease. After extensive counselling with all family 
members, the patient was identified for palliative care and PN was 
weaned and stopped on day 27. 
Figure 1. NICE guidelines for the management of refeeding 
syndrome11,12
NICE* GUIDELINES FOR REFEEDING 
SYNDROME
DAY 1:   10 kcal/kg/day 
  5 kcal/kg/day (BMI < 14 kg/m2 or nil per os for 
   > 15days)
Day 2 to 4: Increase by 5 kcal/kg/day 
  Poor to no tolerance - keep to low feeding  
  regimen or stop
Day 5 to 7: 20–30 kcal/kg/day





Sodium:   restrict < 1 mmol/kg/day
IV Thiamin and B-complex 30 minutes prior to feeding till day  
3 OR 200 mg once when feeding commences and 100 mg daily  
for 10 days 
Fluid balance: maintain at a zero balance
*NICE: National Institute for Health and Care Excellence
Figure 2. Neurology protocols for the management of Wernicke’s 
encephalopathy as recommended by literature4 
European Federation of the Neurological Societies (EFNS): 
200 mg Thiamine IV in 100 ml of normal saline or 5% glucose over 30 
minutes three times a day until symptoms resolve 
Royal College of Physicians:
Evidence based on alcoholics
500 mg Thiamine IV three times a day for three days followed by 250 
mg IV daily for 5 days or until clinical 
improvement is no longer noted 

















1 60 15 1 1.2 0.9
2 60 20 1 2.2 0.9
3 62 25 1.4 3.1 0.9
4–27 66 35 1.9 3.1 0.9
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Literature review 
WE due to thiamin deficiency is common among alcoholics.1,2 Due 
to this association, it is frequently underdiagnosed in non-alcoholic 
patients suffering from gastrointestinal cancers, HIV/AIDS, prolonged 
periods of malnutrition, hyperemesis gravidarum and long term 
total PN.1,2 Sechi et al. found that 75–80% of WE is only diagnosed 
in post-mortem studies.13 Further studies found that inadequate 
thiamin supplementation is administered in 40% of abdominal 
cancer surgery patients.5 Symptoms of a thiamin deficiency or WE 
include acute mental deterioration, ophthalmoplegia, nystagmus and 
ataxia.1-3,4 Onset of symptoms can be expected from two to three 
weeks of poor oral intake, but may also develop two to eight months 
after abdominal cancer surgery.5,9 
Gastric adenocarcinoma patients may present with WE, even in the 
absence of gastrointestinal obstruction, due to severe malnutrition 
and cachexia.1,2 Limitations to current studies include that the signs 
and symptoms identified to contribute to or identify risk of WE could 
be ascribed to other disease conditions and also a lack in sample 
sizes.3 Although Restivo et al. argue a valid point with reference to 
the costs of IV thiamin versus an MRI – that thiamin supplementation 
is cheaper than having each patient at risk of WE sent for a MRI3 – an 
MRI scan is considered to be the preferred diagnostic tool for WE, 
even though it only has a 53% sensitivity.3,13 In this case an MRI was 
done to determine if the patient presented with irreversible features 
of WE. 
Biomarkers to identify thiamin deficiency include plasma thiamin 
levels and, indirectly, from erythrocyte transketolase activity; the 
latter is not used to diagnose WE, but rather as a biomarker of an 
existing deficiency.14 The additional biomarkers were not used or 
tested in this patient as the clinical symptoms adequately justified 
the initiation of thiamin treatment. 
In cancer patients, factors that contribute to the development of 
thiamin deficiency include the consumption of thiamin by fast-
growing neoplastic cells, occlusion or bypassing of the duodenal 
absorptive surface, poor dietary intake related to lack of appetite and 
nausea, significant malabsorption, and the use of specific types of 
chemotherapy.3,15,16 This patient did not receive chemotherapy as the 
cancer was already too advanced on diagnosis, but rather developed 
a deficiency due to the fast growing tumour, prolonged poor intake 
and oral intolerance due to GOO. 
Thiamin is a vital substrate in the anaerobic metabolism of 
carbohydrates, converting pyruvate to acetyl-CoA in the kreb cycle 
to produce adenosine triphosphate (ATP) or suitable energy that is 
transported to the brain.11,12,17 Decreased carbohydrate metabolism 
and poor glucose delivery to the brain lead to poor synaptic 
transmission, altered DNA synthesis and neurotoxicity due to 
increased lactic acid and reactive oxygen species.1-3,4,13,17 Decreased 
blood-brain barrier permeability due to the failed osmotic gradient 
has also been reported as a contributory factor.3 Standard practice 
in patients who present with symptoms of confusion and delirium 
include dextrose IV infusion, that could lead to WE with prolonged 
infusion.17 Large volumes of glucose rapidly deplete already deficient 
stores of thiamin in a malnourished patient, inhibiting glycolysis that 
result in WE.17 Hypomagnesaemia also inhibits the metabolism of 
glucose to ATP, as magnesium is a co-factor that enables thiamin to 
bind to thiamine-dependant enzymes.17 Recommendations include 
glycemic monitoring and early thiamin supplementation when a 
malnourished patient reaches normal glycemic levels.17 PN is often 
required in these patients to deliver adequate nutrition; however, WE 
can also be caused by PN administration due to the increased influx 
of carbohydrates due to refeeding syndrome.1,2,4  
Thiamin body stores are depleted within two to three weeks of 
inadequate intake/ provision and/or increased losses that may lead to 
brain lesions.2,3,4,5,18 Prompt and sufficient thiamin supplementation 
can prevent or reverse early neurological symptoms in the initial two 
to three week stage of reversible biochemical lesions.12,4 In this case 
the patient’s neurological symptoms were partially reversed with 
high-dose thiamin supplementation, irrespective of the advanced 
stage of cancer. A lack of or delay in thiamin replacement can lead 
to irreversible structural lesions in the brain, permanent neurological 
sequelae and death.12,4 More research is needed to determine the 
optimal dosage for thiamin supplementation in treating WE.4 Side 
effects of parenteral thiamin supplementation include pruritus and 
sweating.12,4
Conclusion
Lack of awareness of the manifestation and clinical symptoms 
that present in non-alcoholic thiamin deficiency or WE increase the 
Figure 3. X-ray of failed duodenal self-expanding metal stent (SEMS) 
SEMS compressed by external pressure from tumour
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fatality of the syndrome.1-5,17,18 Gastric adenocarcinoma patients’ life 
expectancy after diagnosis has been extended by improved treatment 
methods,1,2 although all these patients suffer from poor nutritional 
intake and absorption that could lead to nutrient deficiencies. WE or 
thiamin deficiency should be considered in gastric adenocarcinoma 
presenting with prolonged inadequate intake and increased losses in 
order to ensure early supplementation and prevention of permanent 
neurological damage or death. 
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